KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest & Investment Income: 2009-2025

Historic Interest & Investment Income for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $17.9 million.

  • Biomarin Pharmaceutical's Interest & Investment Income fell 1.10% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $74.9 million for FY2024, which is 28.36% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Interest & Investment Income stood at $17.9 million, which was down 5.17% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Interest & Investment Income registered a high of $19.8 million during Q2 2024, and its lowest value of $1.7 million during Q4 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Interest & Investment Income averaged around $17.2 million, with its median value being $18.0 million (2023).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Interest & Investment Income crashed by 54.37% in 2021, and later surged by 556.21% in 2023.
  • Biomarin Pharmaceutical's Interest & Investment Income (Quarterly) stood at $1.7 million in 2021, then skyrocketed by 399.14% to $8.7 million in 2022, then spiked by 107.16% to $18.0 million in 2023, then declined by 2.02% to $17.7 million in 2024, then dropped by 1.10% to $17.9 million in 2025.
  • Its Interest & Investment Income stands at $17.9 million for Q3 2025, versus $18.8 million for Q2 2025 and $19.0 million for Q1 2025.